Pardes Biosciences, an operator of a pre-clinical stage biotechnology company, went public via a SPAC merger with FS Development II, a special purposes acquisition company, in a $276m deal. Investors in PIPE include Foresite Capital, RA Capital Management, Frazier Life Sciences, T. Rowe Price Associates, GMF Capital, EcoR1 Capital, Monashee Investment Management and Gilead Sciences. “We strongly believe in the potential of oral antiviral therapies and the role they will play in addressing both the current pandemic as well as future global health challenges, and believe Pardes is well positioned to help lead the industry towards a post pandemic future. We look forward to Pardes’ continued growth as the company embarks on this next chapter," Jim Tananbaum, FS Development President and CEO.